News|Articles|March 26, 2024

Rare Disease Biotech Landscape

Navigating the unique world of rare disease therapies is like diving into uncharted waters for drug manufacturers. These challenges span multiple stages—from clinical development through commercialization. Overcoming these obstacles require coordinated efforts from medical affairs, health economics and outcomes research, policy, advocacy, and market access to execute successful evidence planning, stakeholder engagement, and patient access strategy.

Avalere, part of Avalere Health, is here to guide you through this exciting journey. In this eBook, Avalere's experts delve into the complexities of rare-disease drug development, the economic challenges, policy landscapes, and innovative approaches to diagnosis and clinical trials.

Fill out the form below to get instant access to the rare disease e-book!

Sponsored by:

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.